Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-23
    E.g., 2018-10-23

Archive Search

2 results
12:00 AM, Nov 16, 2009  |  BC Week In Review | Clinical News  |  Regulatory

Brivudine regulatory update

Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for RESprotect's RP101
SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif.   RESprotect GmbH , Dresden, Germany   Product: Brivudine
12:00 AM, Feb 11, 2008  |  BC Week In Review | Clinical News  |  Regulatory

BVdU regulatory update

FDA granted Orphan Drug designation for RP101 for use as an adjunct to treat pancreatic cancer …
Phase II testing to treat advanced pancreatic cancer. SciClone licensed U.S. and Canadian rights to RP101
Inc. (OTCBB:AVTO), Los Angeles, Calif.   SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), San Mateo, Calif.   Product: BVdU